

To
The Honourable
Mr Dimitrios Lintzeris
President of EOF

Cc: Mr Adonis Georgiadis, Minister of Health
Mrs Christina Papanikolaou, General Secretary of Public health
Mr Georgios Petrikkos, Chairman of the Medicines Prices Committee
Mrs Katerina Fameli, Vice President of EOF

Chalandri, December 19, 2013

Subject: Exclusion of OTC products and products of the negative list from the re-pricing

Dear President Sir,

Further to our letter dated 17/12 in relation to the forthcoming re-pricing of medicinal products, we would like to draw your attention on the exclusion of the OTC products and products of the negative list from the re-pricing.

As you are aware, the cost of these medicinal products is not covered by the insurance Funds, and as non-reimbursed medicinal products, are not included in the pharmaceutical expenditure. Consequently, it is absolutely necessary that they will be **excluded from the re-pricing, taking into account the fact that these products, in their vast majority are old, standard, cheap medicinal products, whose prices are already at the lowest level of the EU countries.** Therefore, any further reduction of their price will certainly incur serious problems, without any substantial benefit.

Yours sincerely,

Constantinos M. Frouzis
President

Nikos Kefalas
Vice President